Cetero Research Acquires Allied Research International, Gains Specialty Clinical ExperienceCARY, N.C.--(BUSINESS WIRE)--Mar 20, 2007 - Cetero Research, the world's largest provider of early clinical and bioanalytical research services for the pharmaceutical industry, has enhanced their early clinical research capabilities with the acquisition of Allied Research International Inc. (ARI), a Toronto-based Contract Research Organization.
Since January 2006, Cetero has built an industry leading early clinical and bioanalytical offering including PRACS Institute, Ltd. of Fargo, ND, Gateway Medical Research of St. Louis, MO, and Ba Research International of Houston, TX.
Cetero currently has 1,400 beds and three bioanalytical laboratories across North America. The merger with Allied Research International adds 210 Phase I beds, four specialty Environmental Exposure Chambers (EEC) used in Allergy research, clinical capacity in Canada, access to patient populations like Asthma, Allergy, Renal disease, Hepatic disease and Diabetes, and additional bioanalytical capacity
"Allied's addition to the Cetero family provides unparalleled depth in our Phase I capabilities, especially with the Environmental Exposure Chambers. These cutting-edge research chambers are world-class clinical units designed and validated to produce a controlled response to allergens while monitoring the effects of the investigational drug. The addition of the Miami clinic offers specialized therapeutic experience and access to patient populations. Cetero has the capacity, the assays, and the scientific and regulatory expertise to support our clients and bringing Allied Research on board significantly enhances what we have to offer our clients," said Jerry Merritt, CEO of Cetero Research.
Cetero offers a full spectrum of early clinical research services to meet the needs of the pharmaceutical and biotechnology industries. Cetero's clinical research capabilities include Label Support studies, Corwatch--a suite of services focused on Cardiac safety, including definitive QTc trials--Environmental Exposure Chambers and Proof-of-Concept trials. Other specialized research service offerings include: Bioanalysis, Dermatology and Scientific Affairs. Cetero's expertise is unrivaled in the early clinical research industry with a foundation of more than 6,000 clinical trials and 24 years of experience.
"In the early clinical research arena, timing and experience are critical. Our capacity, range of services and access to participants including select patient populations allows our customers to do critical studies early and with one CRO. Innovator pharmaceutical companies want to know early, before the expensive Phase IIb and III trials, whether their drug will succeed. Allied's staff and services strengthens our offering and our 24 years of early clinical research experience provide the track record," said John Capicchioni, Vice President of Business Development of Cetero Research.
Headquartered in Toronto, Canada, Allied Research International has been providing services to the pharmaceutical and biotechnology industries since 1989. In 1999, ARI expanded their operation in Toronto with a 76-bed Phase I unit followed by bioanalytical services. In 2006, ARI added a 134-bed Phase I site in Miami, Florida. ARI has experience in Phase I studies, Environmental Exposure Chambers (EEC), Phase II-IV trials, Bioanalytical and Pharmacokinetic research services.
Cetero Research's corporate headquarters are located in Cary, NC. For more information on Cetero Research, please contact John Capicchioni at 201.818.9346 or visit www.cetero.com.
John L. Capicchioni, Vice President, Business Development
Posted: March 2007